Premium
Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress
Author(s) -
Bahrami Afsane,
Khazaei Majid,
Hasanzadeh Malihe,
ShahidSales Soodabeh,
Joudi Mashhad Mona,
Farazestanian Marjaneh,
Sadeghnia Hamid Reza,
Rezayi Majid,
Maftouh Mina,
Hassanian Seyed Mahdi,
Avan Amir
Publication year - 2018
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.25950
Subject(s) - pi3k/akt/mtor pathway , protein kinase b , colorectal cancer , everolimus , mapk/erk pathway , cancer research , medicine , signal transduction , cancer , biology , oncology , microbiology and biotechnology
PI3K/AKT/mTOR signaling pathway is one of the key dysregulated pathways in different tumor types, including colorectal cancer (CRC). Activation of this pathway is shown to be related with cellular transformation, tumor progression, cell survival, and drug resistance. There is growing body of data evaluating the value of PI3K/AKT/mTOR inhibitors in CRC (e.g., BEZ235, NVP‐BEZ235, OSI‐027, everolimus, MK‐2206, KRX‐0401, BYL719, and BKM120). This report summarizes the current knowledge about PI3K/AKT pathway and its cross talk with ERK/MAPK and mTOR pathways with particular emphasis on the value of targeting this pathway as a potential therapeutic target in treatment of colorectal cancer. J. Cell. Biochem. 119: 2460–2469, 2018. © 2017 Wiley Periodicals, Inc.